Ulcerative Colitis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Ulcerative Colitis – Pipeline Review, H1 2020’, provides an overview of the Ulcerative Colitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ulcerative Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis

– The report reviews pipeline therapeutics for Ulcerative Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Ulcerative Colitis therapeutics and enlists all their major and minor projects

– The report assesses Ulcerative Colitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Ulcerative Colitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma Plc

AbbVie Inc

AbGenomics International Inc

Abivax SA

Aclaris Therapeutics Inc

Affilogic SAS

Akebia Therapeutics Inc

Akeso Biopharma Inc

Algernon Pharmaceuticals Inc

Alivio Therapeutics Inc

Allergan Plc

Alpha Cancer Technologies Inc

Alvotech ehf

Am-Pharma BV

Amgen Inc

Antibe Therapeutics Inc

Apidel SA

Applied Molecular Transport LLC

Arena Pharmaceuticals Inc

Artelo Biosciences Inc

AsiaBiome

Asta Pharmaceuticals Co Ltd

Atlantic Bio Sci LLC

Atlantic Healthcare Plc

Avexegen Therapeutics Inc

Axim Biotechnologies Inc

Bilix Co Ltd

BioXpress Therapeutics SA

Boehringer Ingelheim International GmbH

Bridge Biotherapeutics Inc

Bristol-Myers Squibb Co

Cellix Bio Pvt Ltd

Celltrion Inc

Chain Biotechnology Ltd

ChemoCentryx Inc

Chong Kun Dang Pharmaceutical Corp

Circle33 LLC

Cloud Pharmaceuticals Inc

Cosmo Pharmaceuticals NV

Cristcot HCA LLC

CrystalGenomics Inc

Cureveda LLC

Cytocom Inc

Dadang & BIO Co Ltd

DeNovX LLC

Devonian Health Group Inc

DM Bio Ltd

DNX Biopharmaceuticals Inc

Dr. August Wolff GmbH & Co KG Arzneimittel

EA Pharma Co Ltd

Eli Lilly and Co

Enceladus Pharmaceuticals BV

enGene Inc

Exeliom Biosciences SAS

F. Hoffmann-La Roche Ltd

Ferring International Center SA

Finch Therapeutics Group

First Wave Bio Inc

FYB202 GmbH & Co KG

Galapagos NV

Genentech Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

GLW Pharma

Gossamer Bio Inc

Guangzhou Magpie Pharmaceutical Co Ltd

Hefei Cosource Pharmaceutical Inc

Holy Stone Healthcare Co Ltd

Ichnos Sciences Inc

Iltoo Pharma

Immunic Inc

Impetis Biosciences Ltd

Inception Sciences Inc

InDex Pharmaceuticals Holding AB

Innovate Biopharmaceuticals Inc

Innovation Pharmaceuticals Inc

Innovent Biologics Inc

Innovimmune Biotherapeutics Inc

InSight Biopharmaceuticals Ltd

Intact Therapeutics

Intas Pharmaceuticals Ltd

Intract Pharma Ltd

Istesso Ltd

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Kaken Pharmaceutical Co Ltd

Kalytera Therapeutics Inc

Kintai Therapeutics Inc

Koutif Therapeutics LLC

Kyowa Kirin Co Ltd

Landos Biopharma Inc

LG Chem Ltd

LIPID THERAPEUTICS GmbH

LTT Bio-Pharma Co Ltd

MAKScientific LLC

Metacrine Inc

Microbiotica Ltd

Mitsubishi Tanabe Pharma Corp

Morphic Holding Inc

NeuClone Pty Ltd

Nichi-Iko Pharmaceutical Co Ltd

Novartis AG

Nubiyota LLC

Numedii Inc

Nyrada Inc

Oncodesign SA

Oncostellae SL

OSE Immunotherapeutics

Ovamed GmbH

Palatin Technologies Inc

Palo BioFarma SL

Pandion Therapeutics Inc

PanTheryx Inc

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Pharmapraxis

Pharmaxis Ltd

PNB Vesper Life Science Pvt Ltd

Praeventix LLC

Protab Ltd

Protagonist Therapeutics Inc

Protalix BioTherapeutics Inc

Provention Bio Inc

Qu Biologics Inc

Re-Pharm Ltd

Rebiotix Inc

Regentys Corp

ReveraGen BioPharma Inc

RhemaStem SRLS

Salix Pharmaceuticals Ltd

Saniona AB

Sareum Holdings Plc

Semorex Technologies Ltd

Seres Therapeutics Inc

Servatus Ltd

Shaperon Inc

Siam Bioscience Co Ltd

StemRIM Inc

sterna biologicals Gmbh & Co KG

Sublimity Therapeutics HoldCo Ltd

Suzhou Connect Biopharmaceuticals Ltd

Swedish Orphan Biovitrum AB

Synedgen Inc

Synlogic Inc

Takeda Pharmaceutical Co Ltd

Tarus Therapeutics Inc

TheraSource LLC

Theravance Biopharma Inc

Thetis Pharmaceuticals LLC

Tianjin Hemay Pharmaceutical Co Ltd

Tillotts Pharma AG

TopiVert Ltd

Torrent Pharmaceuticals Ltd

Ventria Bioscience

Vivreon Biosciences LLC

Voronoi

Table of Contents

Table of Contents

Introduction

Ulcerative Colitis - Overview

Ulcerative Colitis - Therapeutics Development

Ulcerative Colitis - Therapeutics Assessment

Ulcerative Colitis - Companies Involved in Therapeutics Development

Ulcerative Colitis - Drug Profiles

Ulcerative Colitis - Dormant Projects

Ulcerative Colitis - Discontinued Products

Ulcerative Colitis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Ulcerative Colitis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Ulcerative Colitis – Pipeline by 4D Pharma Plc, H1 2020

Ulcerative Colitis – Pipeline by AbbVie Inc, H1 2020

Ulcerative Colitis – Pipeline by AbGenomics International Inc, H1 2020

Ulcerative Colitis – Pipeline by Abivax SA, H1 2020

Ulcerative Colitis – Pipeline by Aclaris Therapeutics Inc, H1 2020

Ulcerative Colitis – Pipeline by Affilogic SAS, H1 2020

Ulcerative Colitis – Pipeline by Akebia Therapeutics Inc, H1 2020

Ulcerative Colitis – Pipeline by Akeso Biopharma Inc, H1 2020

List of Figures

List of Figures

Number of Products under Development for Ulcerative Colitis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports